Immunovia AB (OSTO:IMMNOV)
kr 0.618 -0.01 (-1.59%) Market Cap: 104.88 Mil Enterprise Value: 76.83 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 44/100

Immunovia AB (publ) Corporate Call Transcript

Mar 30, 2021 / 02:30PM GMT
Release Date Price: kr55.79 (-7.07%)
Operator

Hello, and welcome to Immunovia press conference call. (Operator Instructions) Today, I am pleased to present Patrik Dahlen, CEO; Thomas King, MD, PhD; and Linda Mellby, PhD. Please begin your meeting.

Patrik Dahlen;publ;CEO
Immunovia AB

()-

Thank you very much. Good afternoon, everyone, and thank you for joining us today. And thank you for your continued interest in Immunovia. My name is Patrik Dahlen. I'm the CEO of Immunovia. With me on this call are Thomas King, Dr. Thomas King, who is our Medical Director; and Dr. Linda Mellby, who is our Vice President of R&D. We will be presenting the data from the blinded validation study performed in our Dx Lab in Marlborough, Massachusetts. And we will be presenting the data from a test performance improvement study performed here in the R&D lab in Lund, Sweden.

On the next page, Page 2, please, you can read our disclaimers and our forward-looking statements, and I encourage you to read these at your leisure.

Next page, please, Page 3. Today's agenda is as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot